RecruitingNCT07635316

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Treatment Patterns and Outcomes in GEP NET: A Retrospective Observational Cohort Study (PRIME Initiative)


Sponsor

Novartis Pharmaceuticals

Enrollment

4,023 participants

Start Date

Jun 12, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.


Eligibility

Min Age: 18 YearsMax Age: 110 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with gastroenteropancreatic neuroendocrine tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 110 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Novartis

East Hanover, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07635316


Related Trials